Performance snapshot
Daffodil Software is a well-established offshore development and staff augmentation firm with a broad, multi-decade track record across healthcare, fintech, media, and technology verticals. The majority of reviews reflect strong delivery, communication, and cost-value performance, with most categories rating Strong or Mixed. However, a small but notable cluster of negative reviews — citing non-delivery, persistent bugs, and dishonest project management — introduces reliability concerns that prevent a uniformly Strong profile. The vendor's strongest differentiator is cost-effectiveness paired with consistent responsiveness.
Best for
Daffodil Software is best suited for startups and mid-market companies seeking cost-effective custom software, mobile app development, or IT staff augmentation. It excels in healthcare technology, fintech platforms, and long-term development partnerships requiring flexible, scalable teams.
Clients info
Daffodil Software's clients are concentrated in healthcare technology, fintech, information technology, and advertising and marketing. The predominant client size is small to mid-market, ranging from solo founders and startups to firms with up to 1,000 employees, with several enterprise engagements noted. Project budgets most commonly fall in the $10,000–$199,999 range, with a smaller number of engagements reaching $200,000–$999,999 and two clients in the $1M–$9.9M band. Primary industries represented include Healthcare Technology, Information Technology, Financial Services, Advertising & Marketing, Media, Education, Energy & Natural Resources. Typical client size bands include 1–10 Employees, 11–50 Employees, 51–200 Employees, 201–1,000 Employees. Common project budget ranges include $10,000 to $49,999, $50,000 to $199,999, $200,000 to $999,999.
Review strength
The assessment is based on 96 reviews spanning 4 platforms, with the earliest review dating to 2013 and the most recent to November 2024. The majority of reviews were published between 2016 and 2022, making the evidence base broad but weighted toward older data. Only a small number of reviews are from 2023–2024. Review date range: Jan 2013 - Nov 2024.